^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SynKIR-110

    i
    Other names: SynKIR-110, autologous T cells transduced with mesothelin KIR-CAR
    Company:
    University of Pennsylvania, Verismo Therap
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    27d
    Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110 in Cancer Studies (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Verismo Therapeutics
    New trial
    |
    SynKIR-110
    8ms
    Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesothelioma (SITC 2023)
    These data support further clinical development of SynKIR-110 in patients with advanced solid tumors. SynKIR-110 is currently being investigated in a Phase I clinical trial STAR-101 (NCT05568680).
    Preclinical • CAR T-Cell Therapy
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    SynKIR-110
    1year
    SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
    P1, N=42, Recruiting, Verismo Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Mar 2023
    Enrollment open • Trial initiation date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    SynKIR-110
    over1year
    SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Verismo Therapeutics
    New P1 trial • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    SynKIR-110